BioCentury | Nov 17, 2020
Politics, Policy & Law

Biden appoints former pharma lobbyist Ricchetti as White House counselor

...company. Ricchetti Inc., run by Steve Ricchetti’s brother Jeff Ricchetti, registered as a lobbyist for Eisai Co. Ltd....
...previous years. Steve Usdin Eli Lilly and Co. Pfizer Inc. Genomics Institute of the Novartis Research Foundation Blue Cross Blue Shield Eisai Co. Ltd. Novartis...
BioCentury | Nov 11, 2020
Product Development

Nov. 10 Quick Takes: Tezepelumab meets in asthma Phase III; plus a call for speedy trial results, updates on COVID vaccines from Sinovac, CureVac and more

...and tyrosine kinase inhibitor Lenvima lenvatinib from Eisai Co. Ltd....
BioCentury | Nov 7, 2020
Regulation

Aducanumab panel criticizes FDA as it rebukes Alzheimer’s candidate

...of $50.6 billion.The road aheadSeveral amyloid therapies remain in development for Alzheimer’s, including BAN2401 from Eisai Co. Ltd....
BioCentury | Oct 31, 2020
Product Development

Oct. 30 Quick Takes: Aducanumab heads to EMA; plus Boehringer, Arcus-AZ, Tricida

...By BioCentury Staff EMA accepts aducanumab MAA for reviewBiogen Inc. (NASDAQ:BIIB) and Eisai Co. Ltd. (Tokyo:4523) said the...
...stands at $281.8 million.TARGETSTRPC6 – Transient receptor potential cation channel subfamily C member 6 BC Staff aducanumab (BIIB037) Eisai Co. Ltd. Boehringer...
BioCentury | Oct 28, 2020
Product Development

Data Byte: FOLR1 pipeline for cancer

...a growth advantage. At least one program against FOLR1 has failed a Phase III trial for ovarian cancer. Eisai Co. Ltd....
...Folate receptor 1 Danielle Golovin farletuzumab (MORAb-003) MOv18 IgE mirvetuximab soravtansine (IMGN853) MORAb-202 STRO-002 TPIV200 (TPIV 200, TPIV200/huFR-1) Folate receptor alpha peptide vaccine ImmunoGen Inc. Eisai Co. Ltd. Epsilogen...
BioCentury | Aug 26, 2020
Finance

Partnerships paved the way to a Tokyo IPO for Modalis

...MDL-204 and MDL-206 —  and with Eisai Co. Ltd....
BioCentury | Jul 31, 2020
Distillery Therapeutics

MAO-B, GABRA5 identified as astrocyte targets in subcortical stroke

...from Bausch Health Companies Inc. (TSX:BHC; NYSE:BHC); Eldepryl selegiline from Orion Corp. (HSE:ORNAV; HSE:ORNBV) and Eisai Co. Ltd....
BioCentury | Jul 17, 2020
Finance

July 16 Quick Takes: Biotech stocks fare worse than others in STAR tumble; plus BioAtla, Exalys, Virometix, Biose, Spirea

...either deliver therapies or activate an immune response in specific locations. Exalys debuts with $15M, Eisai...
...with a $15 million series A round and rights to next-generation EP4 receptor antagonists from Eisai Co. Ltd....
BioCentury | Jul 10, 2020
Product Development

Evive meets in Phase III for chemotherapy-induced neutropenia; plus regulatory updates for Biogen, Eisai, Merck, AZ

...in the U.S. and EU. Aducanumab BLA submission for Alzheimer’s completed Biogen Inc. (NASDAQ:BIIB) and Eisai Co. Ltd....
...the mAb against PD-1 is Oct. 30. Merck, Eisai setback for Keytruda-Lenvima combo Merck and Eisai...
...1 Sandi Wong, Assistant Editor Benegrastim (F-627) aducanumab (BIIB037) Keytruda, pembrolizumab (MK-3475, lambrolizumab) Lenvima/Keytruda, lenvatinib mesylate/pembrolizumab Brilinta, Brilique, ticagrelor (AZD6140, Possia) Biogen Inc. Eisai Co. Ltd. Evive...
BioCentury | Jun 11, 2020
Deals

Prism’s peptide mimetic platform finds second discovery partner

...several research collaborations and a licensing deal with Eisai Co. Ltd. (Tokyo:4523). Prism is screening compounds for Eisai...
...1 REST (NRSF) - RE1-silencing transcription factor Elizabeth S. Eaton, Staff Writer PRISM BioLab Co. Ltd. Boehringer Ingelheim GmbH Eisai Co. Ltd. protein-protein...
Items per page:
1 - 10 of 1859
BioCentury | Nov 17, 2020
Politics, Policy & Law

Biden appoints former pharma lobbyist Ricchetti as White House counselor

...company. Ricchetti Inc., run by Steve Ricchetti’s brother Jeff Ricchetti, registered as a lobbyist for Eisai Co. Ltd....
...previous years. Steve Usdin Eli Lilly and Co. Pfizer Inc. Genomics Institute of the Novartis Research Foundation Blue Cross Blue Shield Eisai Co. Ltd. Novartis...
BioCentury | Nov 11, 2020
Product Development

Nov. 10 Quick Takes: Tezepelumab meets in asthma Phase III; plus a call for speedy trial results, updates on COVID vaccines from Sinovac, CureVac and more

...and tyrosine kinase inhibitor Lenvima lenvatinib from Eisai Co. Ltd....
BioCentury | Nov 7, 2020
Regulation

Aducanumab panel criticizes FDA as it rebukes Alzheimer’s candidate

...of $50.6 billion.The road aheadSeveral amyloid therapies remain in development for Alzheimer’s, including BAN2401 from Eisai Co. Ltd....
BioCentury | Oct 31, 2020
Product Development

Oct. 30 Quick Takes: Aducanumab heads to EMA; plus Boehringer, Arcus-AZ, Tricida

...By BioCentury Staff EMA accepts aducanumab MAA for reviewBiogen Inc. (NASDAQ:BIIB) and Eisai Co. Ltd. (Tokyo:4523) said the...
...stands at $281.8 million.TARGETSTRPC6 – Transient receptor potential cation channel subfamily C member 6 BC Staff aducanumab (BIIB037) Eisai Co. Ltd. Boehringer...
BioCentury | Oct 28, 2020
Product Development

Data Byte: FOLR1 pipeline for cancer

...a growth advantage. At least one program against FOLR1 has failed a Phase III trial for ovarian cancer. Eisai Co. Ltd....
...Folate receptor 1 Danielle Golovin farletuzumab (MORAb-003) MOv18 IgE mirvetuximab soravtansine (IMGN853) MORAb-202 STRO-002 TPIV200 (TPIV 200, TPIV200/huFR-1) Folate receptor alpha peptide vaccine ImmunoGen Inc. Eisai Co. Ltd. Epsilogen...
BioCentury | Aug 26, 2020
Finance

Partnerships paved the way to a Tokyo IPO for Modalis

...MDL-204 and MDL-206 —  and with Eisai Co. Ltd....
BioCentury | Jul 31, 2020
Distillery Therapeutics

MAO-B, GABRA5 identified as astrocyte targets in subcortical stroke

...from Bausch Health Companies Inc. (TSX:BHC; NYSE:BHC); Eldepryl selegiline from Orion Corp. (HSE:ORNAV; HSE:ORNBV) and Eisai Co. Ltd....
BioCentury | Jul 17, 2020
Finance

July 16 Quick Takes: Biotech stocks fare worse than others in STAR tumble; plus BioAtla, Exalys, Virometix, Biose, Spirea

...either deliver therapies or activate an immune response in specific locations. Exalys debuts with $15M, Eisai...
...with a $15 million series A round and rights to next-generation EP4 receptor antagonists from Eisai Co. Ltd....
BioCentury | Jul 10, 2020
Product Development

Evive meets in Phase III for chemotherapy-induced neutropenia; plus regulatory updates for Biogen, Eisai, Merck, AZ

...in the U.S. and EU. Aducanumab BLA submission for Alzheimer’s completed Biogen Inc. (NASDAQ:BIIB) and Eisai Co. Ltd....
...the mAb against PD-1 is Oct. 30. Merck, Eisai setback for Keytruda-Lenvima combo Merck and Eisai...
...1 Sandi Wong, Assistant Editor Benegrastim (F-627) aducanumab (BIIB037) Keytruda, pembrolizumab (MK-3475, lambrolizumab) Lenvima/Keytruda, lenvatinib mesylate/pembrolizumab Brilinta, Brilique, ticagrelor (AZD6140, Possia) Biogen Inc. Eisai Co. Ltd. Evive...
BioCentury | Jun 11, 2020
Deals

Prism’s peptide mimetic platform finds second discovery partner

...several research collaborations and a licensing deal with Eisai Co. Ltd. (Tokyo:4523). Prism is screening compounds for Eisai...
...1 REST (NRSF) - RE1-silencing transcription factor Elizabeth S. Eaton, Staff Writer PRISM BioLab Co. Ltd. Boehringer Ingelheim GmbH Eisai Co. Ltd. protein-protein...
Items per page:
1 - 10 of 1859